Tempest Therapeutics, Inc. (TPST) stock
Close on Nov 11, 2026Market cap $5.88MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $5.88M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -352.65%
Fundamentals
- Net income
- -$40.47M
- EPS, diluted
- -$4.48
- Free cash flow
- -$20.73M
- Book value per share
- -$0.07
- Diluted shares
- 15M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.37
- Open
- $0.42
- Day's range
- $0.38 – $0.48
- Volume
- 1,481,027
- Average volume (20 days)
- 219,096
- Beta (5 years)
- 2.07
- 52-week range
- $0.34 – $9.75
- RSI (14 days)
- 28.8
- Volatility (1 year)
- 127.0%
- Relative volume
- 0.78×
- WACC
- 15.2%
Market cap history
Month-end market cap since 2012, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | TPST | S&P 500 | Difference | TPST per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -47.8% | -2.4% | −45.4 pts | ||
| 3 months | -66.4% | -1.2% | −65.2 pts | ||
| Year to date | -86.2% | +12.3% | −98.5 pts | ||
| 1 year | -95.9% | +12.4% | −108.3 pts | ||
| 3 years | -99.1% | +78.8% | −177.9 pts | -78.8% | +21.4% |
| 5 years | -99.7% | +75.2% | −174.9 pts | -69.5% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -63.9% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tempest Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Results
- Update
- Update
About Tempest Therapeutics
Pharmaceutical Preparations
Tempest Therapeutics is a clinical-stage biotechnology company that develops targeted therapies for oncology and immunology indications. The company focuses on advancing cell therapy and small-molecule product candidates. Its primary cell therapy programs include TPST-2003, an autologous dual-targeting CAR-T therapy evaluated for relapsed or refractory multiple myeloma and POEMS syndrome, alongside additional autologous, allogeneic, and in vivo CAR-T candidates targeting conditions like solid tumors and lupus. Tempest also advances two clinical-stage small-molecule candidates, amezalpat, an oral PPARα antagonist evaluated for hepatocellular carcinoma, and TPST-1495, an oral dual antagonist of EP2 and EP4 receptors evaluated for familial adenomatous polyposis. Its therapies are designed for patients facing high unmet medical needs in oncology and related fields.
Company profile, executives and historyTempest Therapeutics stock: common questions
What is Tempest Therapeutics's stock price?
TPST closed at $0.40 on Nov 11, 2026, up 6.09% on the day. Over the past 52 weeks it traded between $0.34 and $9.75.
What is Tempest Therapeutics's market cap?
Tempest Therapeutics was worth $5.88M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is TPST's P/E ratio?
Tempest Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$4.48), so it has no meaningful P/E ratio.
Does Tempest Therapeutics pay a dividend?
No. Tempest Therapeutics has not paid a cash dividend over the last twelve months.
When does Tempest Therapeutics report earnings next?
Tempest Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has TPST stock performed over the past year?
Including dividends, TPST returned -95.9% over the past year, against +12.4% for the S&P 500.
How many TPST shares are sold short?
0M shares were sold short at the latest FINRA report, 2.67% of the float, or 1.9 days of average trading volume.
Who are Tempest Therapeutics's competitors?
Companies most similar to Tempest Therapeutics by business, industry and size include LYEL, IMNM, RCUS, CNTX, PRLD.
See a number that looks wrong?